Note 6 - Accrued Expenses

3 Months Ended

Mar. 31, 2025

Notes to Financial Statements

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

6. Accrued Expenses

Accrued expenses consist of the following (in thousands):

	March 31,		December 31,
	2025		2024
Project expenses	$	11,448	$	2,873
Compensation and benefits		1,492		2,793
Other		274		621
Total accrued expenses	$	13,214	$	6,287

Project expenses includes $10.4 million of accrued manufacturing expenses and $1.0 million of accrued clinical expenses primarily related to tovecimig.